Dataset Information

Biomarkers discovery for Colorectal cancer liver metastasis

ABSTRACT: Identification of early diagnostic and prognostic biomarkers measurable in liquid biopsies remains a major challenge in oncology today. OMICs technologies cannot be applied on clinically precious human material as this is required in its integrity for routine pathology investigation. Hence all OMICs discovery today is done on residual and not clinically relevant material. In the study, we present a novel, non-destructive, procedure named EXPEL, which uses rapid, pressure-assisted, interstitial fluid extrusion, allowing for full clinical pathology and OMICs analysis (proteins, metabolites, miRNA and DNA) on the same specimen. To demonstrate this we engage in a simultaneous biomarker discovery and routine diagnostic analysis of human colorectal cancer and liver metastases. Biomarkers discovered with EXPEL methodology can be readily detected in human sera, allowing for unprecedented translation to the clinic. EXPEL method enables for the first time both clinicians and scientist to explore identical, fresh, clinical material regardless of origin and size.

INSTRUMENT(S): Q Exactive

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Liver

DISEASE(S): Colon Cancer

SUBMITTER: Dominique Baiwir

LAB HEAD: Vincent Castronovo

PROVIDER: PXD005709 | Pride | 2018-10-26

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	150130-15_0321-01-AKZ-F01.raw	Raw
	150130-15_0321-01-AKZ-F02.raw	Raw
	150130-15_0321-01-AKZ-F03.raw	Raw
	150130-15_0325-01-AKZ-F01_150203130716.raw	Raw
	150130-15_0325-01-AKZ-F02.raw	Raw

Items per page:

1 - 5 of 38

Publications

Innovative methodology for the identification of soluble biomarkers in fresh tissues.

Costanza Brunella B Turtoi Andrei A Bellahcène Akeila A Hirano Touko T Peulen Olivier O Blomme Arnaud A Hennequière Vincent V Mutijima Eugene E Boniver Jacques J Meuwis Marie-Alice MA Josse Claire C Koopmansch Benjamin B Segers Karin K Yokobori Takehiko T Fahmy Karim K Thiry Marc M Coimbra Carla C Garbacki Nancy N Colige Alain A Baiwir Dominique D Bours Vincent V Louis Edouard E Detry Olivier O Delvenne Philippe P Nishiyama Masahiko M Castronovo Vincent V

Oncotarget 20180131 12

The identification of diagnostic and prognostic biomarkers from early lesions, measurable in liquid biopsies remains a major challenge, particularly in oncology. Fresh human material of high quality is required for biomarker discovery but is often not available when it is totally required for clinical pathology investigation. Hence, all OMICs studies are done on residual and less clinically relevant biological samples. Here after, we present an innovative, simple, and non-destructive, procedure ...[more]

PMID: 29535834

Similar Datasets

Project description:Stroke remains a major leading cause of death and disability worldwide. Despite continuous advances, the identification of key molecular signatures of ischemic stroke within the hyper-acute phase of the disease is still of primary interest for a real translational research on stroke diagnosis, prognosis and treatment. High-throughput - omics technologies are enabling large-scale studies on stroke pathology at different molecular levels. Data integration resulting from these -omics approaches is becoming crucial to unravel the interactions among all different molecular elements and highly contribute to interpret all findings in a complex biological context. Here, we have used advanced data integration methods for multi-level joint analysis of transcriptomics and proteomics datasets depicted from the mouse brain 2h after cerebral ischemia. By modeling network-like correlation structures, we identified a set of differentially expressed genes and proteins by ischemia with a relevant association in stroke pathology. The ischemia-induced deregulation of 10 of these inter-correlated elements was successfully verified in a new cohort of ischemic mice, and changes in their expression pattern were also evaluated at a later time-point after cerebral ischemia. Of those, CLDN20, GADD45G, RGS2, BAG5 and CTNND2 were highlighted and evaluated as potential blood biomarkers of cerebral ischemia in blood samples from ischemic and sham-control mice and from ischemic strokes and other patients presenting stroke-mimicking conditions. Our findings indicated that CTNND2 and GADD45G levels in blood within the first hours after ischemic stroke might be potentially useful to discriminate ischemic strokes from mimics and to predict patients’ poor outcome after stroke, respectively. In summary, we have here used for the first time an integrative approach to elucidate by means of biostatistical tools key elements of the initial stages of the stroke pathophysiology, highlighting new outstanding proteins that might be further considered as blood biomarkers of ischemic stroke.